1 Name#
This instrument is the National Health (Price and Special Patient Contribution) Amendment Determination (No. 10) 2026.
This instrument may also be cited as PB 133 of 2026.
2Commencement#
(1)Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.
| Commencement information | ||
|---|---|---|
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. The whole of this instrument | 1 November 2026 |
Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.
(2)Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.
4 Schedules#
Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.
Schedule 1 – Amendments
National Health (Price and Special Patient Contribution) Determination 2022 (PB 98 of 2022)
Omit
| Medroxyprogesterone | Tablet containing medroxyprogesterone acetate 5 mg | Oral | Provera | 56 | 5.10 | 9.36 |
| Tablet containing medroxyprogesterone acetate 10 mg | Oral | Provera | 30 | 6.39 | 12.62 |
Insert
| Medroxyprogesterone | Tablet containing medroxyprogesterone acetate 10 mg | Oral | Provera | 30 | 6.39 | 12.62 |
Omit
| Meloxicam | Capsule 7.5 mg | Oral | Mobic | 30 | 3.10 | 5.89 |
| Capsule 15 mg | Oral | Mobic | 30 | 3.80 | 6.59 | |
| Tablet 7.5 mg | Oral | Mobic | 30 | 3.10 | 5.89 | |
| Tablet 15 mg | Oral | Mobic | 30 | 3.80 | 6.59 |
Insert
| Meloxicam | Capsule 7.5 mg | Oral | Mobic | 30 | 3.10 | 5.89 |
| Tablet 7.5 mg | Oral | Mobic | 30 | 3.10 | 5.89 | |
| Tablet 15 mg | Oral | Mobic | 30 | 3.80 | 6.59 |
Omit
| Olmesartan with amlodipine and hydrochlorothiazide | Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 12.5 mg | Oral | Sevikar HCT 20/5/12.5 | 30 | 5.57 | 9.29 |
| Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 12.5 mg | Oral | Sevikar HCT 40/5/12.5 | 30 | 8.21 | 11.93 | |
| Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 25 mg | Oral | Sevikar HCT 40/5/25 | 30 | 9.66 | 13.38 | |
| Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 12.5 mg | Oral | Sevikar HCT 40/10/12.5 | 30 | 8.59 | 12.56 | |
| Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 25 mg | Oral | Sevikar HCT 40/10/25 | 30 | 10.02 | 13.74 |
Insert
| Olmesartan with amlodipine and hydrochlorothiazide | Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 25 mg | Oral | Sevikar HCT 40/5/25 | 30 | 9.66 | 13.38 |
| Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 12.5 mg | Oral | Sevikar HCT 40/10/12.5 | 30 | 8.59 | 12.56 |
Omit
| Trandolapril | Capsule 500 micrograms | Oral | Gopten | 28 | 2.50 | 5.76 |
| Capsule 1 mg | Oral | Gopten | 28 | 3.69 | 6.95 | |
| Capsule 2 mg | Oral | Gopten | 28 | 4.45 | 7.70 | |
| Capsule 4 mg | Oral | Gopten | 28 | 8.36 | 11.61 |
Insert
| Trandolapril | Capsule 500 micrograms | Oral | Gopten | 28 | 2.50 | 5.76 |
| Capsule 1 mg | Oral | Gopten | 28 | 3.69 | 6.95 | |
| Capsule 2 mg | Oral | Gopten | 28 | 4.45 | 7.70 |
Sourced from the Federal Register of Legislation at legislation.gov.au, © Commonwealth of Australia, licensed under CC BY 4.0. Compilations may have been reformatted.